Latest First Analysis news

Venture capital Cybersecurity
Gradient Cyber News

First Analysis invests in Gradient Cyber, provider of MXDR services for mid-market organizations

First Analysis, a leading venture capital investor, has made a new investment in Gradient Cyber, a leading provider of managed extended detection and response (MXDR) services for mid-market organizations. First Analysis led the Series A financing, which will support Gradient Cyber’s continued growth and product development as it scales to meet increasing demand for 24/7 MXDR services.
Learn more: First Analysis invests in Gradient Cyber, provider of MXDR services for mid-market organizations Load More : First Analysis invests in Gradient Cyber, provider of MXDR services for mid-market organizations
Venture capital
Fa2025 Element

First Analysis closes on Fund XIV at $97 million in committed capital

First Analysis, a leading venture capital firm specializing in B2B technology investments, announced today the closing of its 14th fund, at $97 million in committed capital. First Analysis again committed substantial capital to its own fund, making it the largest investor in the new fund and underscoring its continued confidence in its distinctive investment approach.
Learn more: First Analysis closes on Fund XIV at $97 million in committed capital Load More : First Analysis closes on Fund XIV at $97 million in committed capital
Venture capital Enterprise productivity
PCMI

First Analysis portfolio company PCMI receives strategic growth investment from Thoma Bravo

Thoma Bravo, a leading software investment firm, has made a strategic growth investment in PCMI, a portfolio company of First Analysis and Equality Asset Management. PCMI is a leading provider of administration software for finance and insurance products in the automotive and consumer end markets. Thoma Bravo’s expertise in scaling technology companies will help accelerate PCMI’s global growth and support its efforts in enhancing the platform. William Blair acted as the exclusive financial advisor to PCMI.
Learn more: First Analysis portfolio company PCMI receives strategic growth investment from Thoma Bravo Load More : First Analysis portfolio company PCMI receives strategic growth investment from Thoma Bravo
Venture capital Enterprise productivityFuture of work
Amplifund

First Analysis portfolio company AmpliFund has been acquired by Euna Solutions

Euna Solutions, a provider of SaaS solutions purpose-built for the public sector, has acquired First Analysis portfolio company AmpliFund, a leading grant management platform provider. This strategic move enhances Euna Solutions’ existing grant management product suite, further solidifying its commitment to delivering innovative and comprehensive tools for government agencies, nonprofits and other public sector organizations.
Learn more: First Analysis portfolio company AmpliFund has been acquired by Euna Solutions Load More : First Analysis portfolio company AmpliFund has been acquired by Euna Solutions
Investment banking Healthcare IT
Tbx Tombstone 2025

First Analysis acted as the exclusive financial advisor to TBX® in its sale to Selerix

First Analysis acted as the exclusive financial advisor to The Benefits eXpert® (TBX®), an employee benefits technology company that offers an engagement, education and administrative platform, in its sale to Selerix, a provider of cloud-based benefits administration and communications solutions.
Learn more: First Analysis acted as the exclusive financial advisor to TBX® in its sale to Selerix Load More : First Analysis acted as the exclusive financial advisor to TBX® in its sale to Selerix
Investment banking Healthcare IT
Upfront 2025

First Analysis acted as the exclusive financial advisor to Upfront Healthcare in its sale to Health Catalyst

First Analysis acted as the exclusive financial advisor to Upfront Healthcare Services (Upfront), a next-generation patient engagement platform provider, in its sale to Health Catalyst (Nasdaq: HCAT), a provider of data and analytics technology and services to healthcare organizations.
Learn more: First Analysis acted as the exclusive financial advisor to Upfront Healthcare in its sale to Health Catalyst Load More : First Analysis acted as the exclusive financial advisor to Upfront Healthcare in its sale to Health Catalyst
Venture capital Healthcare IT
Visiquate

First Analysis portfolio company VisiQuate has been acquired by Accel-KKR

Accel-KKR has acquired First Analysis portfolio company VisiQuate, a provider of advanced revenue cycle analytics, AI-powered workflow and automation solutions. The strategic partnership leverages Accel-KKR’s extensive resources and strategic expertise to accelerate product innovation and expand VisiQuate’s team.
Learn more: First Analysis portfolio company VisiQuate has been acquired by Accel-KKR Load More : First Analysis portfolio company VisiQuate has been acquired by Accel-KKR
Venture capital Pharma IT
Applied Logo 2 Gfx 16072024080730

First Analysis invests in Applied StemCell, a leading cell and gene therapy CRO/CDMO

First Analysis, a leading venture capital investor, has made a new investment in Applied StemCell (ASC), a contract development and manufacturing organization (CDMO) specializing in tailored cell and gene therapy solutions. First Analysis co-invested in ASC alongside QHP Capital.
Learn more: First Analysis invests in Applied StemCell, a leading cell and gene therapy CRO/CDMO Load More : First Analysis invests in Applied StemCell, a leading cell and gene therapy CRO/CDMO
Venture capital Pharma IT
Sware

First Analysis invests in Sware, provider of FDA-mandated computer system validation automation for GxP systems and release testing

First Analysis, a leading venture capital investor, has made a new investment in Sware, which provides a complete software validation solution for innovative life sciences companies. The investment will be used to bolster research and development of Sware’s computer systems validation (CSV) platform, Res_Q, to further streamline processes with artificial intelligence (AI), and to expand the company’s sales team so it can bring the platform to more organizations struggling with validation debt.
Learn more: First Analysis invests in Sware, provider of FDA-mandated computer system validation automation for GxP systems and release testing Load More : First Analysis invests in Sware, provider of FDA-mandated computer system validation automation for GxP systems and release testing